Inventiva Sa

IVA · NASDAQ · Healthcare / Biotechnology

3.68USD-0.20 (-5.15%)

Price History

Full chart

Market Stats

Previous Close3.88

Open3.86

Day Range3.67 – 3.88

52-Week Range3.11 – 7.98

Volume3.32M

Market Cap833.86M

P/E (TTM)0.00

Forward P/E0.00

EPS-2.26

Dividend Yield0.00%

Beta0.92

50-Day Avg4.40

200-Day Avg5.04

About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Andrew Obenshain
Employees69
Headquarters50 rue de Dijon, Daix, France, 21121, USA
Websitehttps://inventivapharma.com

Leadership

Mr. Andrew ObenshainChief Executive Officer · b. 1974
Dr. Pierre Broqua Ph.D.Co-Founder · b. 1962
Mr. Jean VolatierExecutive VP Finance & Corporate Social Responsibility · b. 1965
Dr. Martine Zimmermann Pharm.D.Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs · b. 1969
Mr. Jason A. Campagna M.D., Ph.D.President of Research & Development and Chief Medical Officer · b. 1966
Mr. Axel-Sven MalkomesChief Financial Officer · b. 1967
Ms. Susan ColesChief Legal Officer · b. 1966
Ms. Pamela HerbsterChief People Officer
Ms. Nazira Amra M.D.Chief Commercial Strategy Officer

Financials

Income Statement

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	3.06M	3.28M	4.87M	9.45M	6.52M	3.20M	7.00M	372.00K	4.19M	12.18M	17.48M	9.20M	4.48M
Growth (%)	-	+7.13%	+48.49%	+93.77%	-30.96%	-50.97%	+118.89%	-94.68%	+1027.42%	+190.39%	+43.50%	-47.37%	-51.26%
Cost of Revenue	1.68M	1.52M	1.40M	1.49M	1.24M	967.00K	-	846.00K	1.02M	995.00K	-23.00K	3.88M	2.80M
Gross Profit	1.38M	1.76M	3.47M	7.96M	5.28M	2.23M	7.00M	372.00K	4.19M	12.18M	17.50M	9.20M	1.51M
Gross Margin	45.11%	53.59%	71.18%	84.27%	81.05%	69.75%	100.00%	100.00%	100.00%	100.00%	100.13%	100.00%	33.68%
Operating Expense	13.85M	15.23M	18.98M	20.98M	26.20M	35.48M	37.31M	30.09M	56.31M	69.29M	120.21M	106.76M	132.46M
Operating Income	-12.47M	-13.47M	-15.51M	-13.02M	-20.92M	-33.25M	-30.31M	-29.72M	-52.11M	-57.11M	-102.71M	-97.56M	-130.95M
Operating Margin	-406.81%	-410.22%	-318.17%	-137.83%	-320.76%	-1040.13%	-433.15%	-7988.71%	-1242.58%	-468.92%	-587.68%	-1060.64%	-2920.96%
EBITDA	-11.42M	-12.43M	-13.91M	-11.14M	-22.00M	-32.04M	-28.76M	-27.83M	-52.76M	-55.41M	-102.04M	-166.53M	-128.15M
EBITDA Margin	-372.51%	-378.48%	-285.28%	-117.98%	-337.37%	-1002.22%	-410.95%	-7481.18%	-1258.04%	-454.98%	-583.86%	-1810.45%	-2858.59%
Net Income	-7.13M	-7.49M	-8.82M	-7.05M	-17.23M	-33.62M	-30.22M	-31.62M	-49.64M	-54.27M	-110.43M	-184.21M	-340.16M
Net Income Margin	-232.82%	-228.26%	-181.00%	-74.59%	-264.22%	-1051.49%	-431.85%	-8500.81%	-1183.50%	-445.64%	-631.84%	-2002.74%	-7587.80%
R&D	13.75M	16.28M	19.64M	22.14M	26.73M	31.64M	33.79M	23.72M	48.45M	60.47M	110.01M	90.88M	83.61M
R&D as % of Total Revenue	448.59%	496.01%	402.89%	234.44%	409.96%	989.58%	482.87%	6375.54%	1155.27%	496.50%	629.47%	988.04%	1864.99%
Interest Expense	630	2.94K	6.06K	7.55K	5.32K	243.03K	3.00K	66.00K	138.00K	707.00K	5.18M	12.18M	32.30M
Interest Expense % of Total Revenue	0.02%	0.09%	0.12%	0.08%	0.08%	7.60%	0.04%	17.74%	3.29%	5.81%	29.63%	132.40%	720.41%

Balance Sheet

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	87.12M	73.13M	60.58M	48.86M	74.37M	79.81M	56.96M	138.92M	121.98M	116.00M	69.56M	118.97M	248.88M
Total Liabilities	28.11M	21.63M	17.81M	13.14M	10.36M	18.22M	15.57M	27.71M	33.12M	70.53M	101.59M	225.61M	277.91M
Total Equity	59.01M	51.51M	42.77M	35.72M	64.01M	61.60M	41.39M	111.21M	88.87M	45.48M	-32.03M	-106.65M	-29.04M
Cash	13.52M	17.14M	22.60M	24.87M	59.05M	56.69M	35.84M	105.69M	86.55M	86.74M	26.92M	96.56M	99.27M
Total Debt	160.39K	104.46K	698.00K	627.60K	482.13K	2.20M	114.00K	10.06M	10.12M	34.51M	37.49M	54.33M	59.40M
Net Debt	-13.36M	-17.03M	-21.90M	-24.24M	-58.57M	-54.49M	-35.73M	-92.43M	-76.43M	-52.22M	10.57M	-42.23M	-39.87M

Cash Flow

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-16.01M	-14.79M	-13.98M	-14.86M	-17.00M	-34.21M	-28.40M	-30.59M	-47.63M	-44.93M	-81.61M	-85.93M	-100.98M
Investing Cash Flow	18.37M	18.46M	18.85M	17.20M	6.17M	-420.00K	-826.00K	-8.56M	-1.79M	8.87M	-7.73M	8.74M	-127.93M
Financing Cash Flow	240.49K	-60.49K	591.84K	-70.86K	45.01M	32.27M	8.38M	111.67M	25.45M	37.27M	29.08M	145.59M	232.00M
Capital Expenditure	1.92M	1.29M	968.99K	227.94K	428.03K	549.00K	136.00K	292.00K	534.00K	561.00K	540.00K	333.00K	237.25K
Free Cash Flow	-17.93M	-16.08M	-14.95M	-15.09M	-17.43M	-34.76M	-28.54M	-30.88M	-48.16M	-45.49M	-82.15M	-86.26M	-101.22M
Dividends Paid	-	-	-	0	-	-	-	-	-	-	0	0	0
FCF to OCF	111.99%	108.73%	106.93%	101.53%	102.52%	101.60%	100.48%	100.95%	101.12%	101.25%	100.66%	100.39%	100.23%
Dividend Paid to FCF	-	-	-	0.00%	-	-	-	-	-	-	0.00%	0.00%	0.00%

Earnings

Report Date	May 15, 2019	May 14, 2020	Sep 16, 2020	Nov 12, 2020	Mar 4, 2021	May 12, 2021	Sep 20, 2021	Nov 10, 2021	Mar 10, 2022	May 16, 2022	Sep 22, 2022	Nov 10, 2022	Mar 29, 2023	May 16, 2023	Sep 28, 2023	Nov 21, 2023	Mar 27, 2024	May 21, 2024	Sep 25, 2024	Nov 21, 2024	Mar 26, 2025	Apr 15, 2025	Sep 29, 2025	Nov 21, 2025	Mar 30, 2026	May 25, 2026	Sep 25, 2026
EPS Estimate	0.00	0.00	-0.45	-0.38	-0.48	-0.33	-0.82	-0.36	-0.48	0.00	0.00	0.00	0.08	-0.29	-1.39	-0.98	-0.40	-0.47	-0.63	-0.56	-0.43	-0.43	-0.60	-0.29	-0.34	-0.34	-0.20
EPS Actual	0.00	-0.27	-0.21	-0.39	-0.48	-0.44	0.00	0.00	-0.16	0.00	0.00	0.00	-0.28	-0.29	-1.39	-0.98	-0.64	-0.48	-0.87	-0.76	-1.82	-2.00	-1.62	-0.30	0.00	0.00	-
Surprise	-	-	53.33%	-3.94%	0.00%	-32.33%	100.00%	100.00%	66.67%	-	-	-	-444.75%	0.00%	0.00%	0.00%	-60.30%	-2.13%	-37.74%	-35.71%	-323.26%	-365.12%	-167.86%	-3.45%	100.00%	100.00%	-
Timing	-	-	After-hours	-	-	-	-	-	After-hours	-	-	-	-	-	-	-	After-hours	After-hours	-	-	-	-	After-hours	-	-	-	After-hours

Key Statistics & Ratios

Market Cap833.86M

Enterprise Value615.52M

Trailing P/E0.00

Forward P/E0.00

Price / Sales123.33

Price / Book2.10

EPS-2.26

Book Value-0.1715

Revenue (TTM)6.76M

Gross Profit (TTM)6.74M

EBITDA-132.50M

Profit Margin0.00%

Operating Margin-6710.69%

Return on Equity-1642.76%

Return on Assets-45.08%

Shares Outstanding236.22M

Shares Float157.92M

Beta0.92

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Strong Buy

Based on 7 analystsTarget 14.96

Strong Buy
6
Hold
1

Ownership Breakdown

Institutions: 41.80%
Insiders: 0.00%
Retail / Other: 58.20%

Top Institutional Holders

Caligan Partners LP
8.16M3.46%
Samsara BioCapital, LLC
6.31M2.67%
Paradigm Biocapital Advisors LP
4.00M1.69%
Andera Partners
3.63M1.54%
Millennium Management LLC
3.51M1.49%
Trails Edge Capital Partners, LP
2.66M1.13%
Franklin Templeton Inc
2.46M1.04%
Squadron Capital Management LLC
2.44M1.03%
SymBiosis Capital Partners, LLC
2.35M1.00%
UBS Group AG
2.32M0.98%
Aberdeen Group PLC
2.31M0.98%
ADAR1 Capital Management LLC
2.17M0.92%
Polar Capital Holdings PLC
2.13M0.90%
Patient Square Capital LP
1.97M0.83%
NEXTBio Capital Management LP
1.79M0.76%
Citadel Advisors Llc
1.78M0.76%
Integral Health Asset Management, LLC
1.52M0.64%
Yu Fan
1.50M0.64%
BOOTHBAY FUND MANAGEMENT, LLC
1.47M0.62%

Top Fund Holders

Franklin Biotechnology Discv A(acc)USD
1.93M0.82%